5 min read
Therapeutic Thursday: A Bad Day At The Office
Two Phase III failures in a week. A $12bn acquisition under scrutiny. A patent cliff. Novartis has had better Septembers.
Two Phase III failures in a week. A $12bn acquisition under scrutiny. A patent cliff. Novartis has had better Septembers.